| scholarly article | Q13442814 |
| P2093 | author name string | Morrissey JH | |
| Comp PC | |||
| Neuenschwander PF | |||
| Macik BG | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 734-744 | |
| P577 | publication date | 1993-02-01 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation | |
| P478 | volume | 81 |
| Q90182302 | A candidate activation pathway for coagulation factor VII |
| Q85074568 | Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy |
| Q37218884 | Anticoagulation Therapy Considerations in Factor VII Deficiency |
| Q37886448 | Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors |
| Q47981795 | Associations of activated coagulation factor VII and factor VIIa-antithrombin levels with genome-wide polymorphisms and cardiovascular disease risk. |
| Q34150160 | Autonomic function and prothrombotic activity in women after an acute coronary event |
| Q33585249 | Biology of tissue factor pathway inhibitor. |
| Q33328717 | Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1 |
| Q91934049 | Characterization of the enzymatic activity of the serine protease domain of Factor VII activating protease (FSAP) |
| Q35489598 | Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events |
| Q35775912 | Coagulation in sepsis |
| Q35911478 | Decryption of tissue factor |
| Q53561695 | Effect of interesterification of palmitic acid-rich triacylglycerol on postprandial lipid and factor VII response. |
| Q38138876 | Emerging paradigms in arterial thrombosis |
| Q36484525 | Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa |
| Q40357741 | Evening primrose oil or forskolin ameliorates celecoxib-enhanced upregulation of tissue factor expression in mice subjected to lipopolysaccharide-induced endotoxemia. |
| Q24336746 | FVII, FVIIa, and downstream markers of extrinsic pathway activation differ by EPCR Ser219Gly variant in healthy men |
| Q33608210 | Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy |
| Q38757815 | Factor VII and incidence of myocardial infarction in a Japanese population: The Jichi Medical School Cohort Study. |
| Q41976376 | Factor VII mutant V154G models a zymogen-like form of factor VIIa. |
| Q43001454 | Fusion of two distinct peptide exosite inhibitors of Factor VIIa |
| Q37377341 | Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease |
| Q35581311 | Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. |
| Q36783613 | How it all starts: Initiation of the clotting cascade. |
| Q64910116 | Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice. |
| Q42202751 | Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation |
| Q46943994 | Influence of stearic acid on postprandial lipemia and hemostatic function |
| Q37570030 | Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. |
| Q28360273 | Is activated factor VII associated with retinal vein occlusion? |
| Q33801932 | Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know |
| Q42011864 | Localization of Short-Chain Polyphosphate Enhances its Ability to Clot Flowing Blood Plasma. |
| Q79157796 | Low levels of activated factor VII in systemic sclerosis |
| Q36916334 | NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. |
| Q43594298 | Oral factor Xa inhibitors for the long-term management of ACS. |
| Q36981748 | Overview of the human pharmacokinetics of recombinant activated factor VII. |
| Q35746146 | P-selectin induces the expression of tissue factor on monocytes |
| Q34458349 | Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia |
| Q35544621 | Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding |
| Q37586365 | Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog. |
| Q34630452 | Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor |
| Q48122836 | Polyphosphate and RNA Differentially Modulate the Contact Pathway of Blood Clotting. |
| Q35639584 | Posttranslational modifications of tissue factor |
| Q34538372 | Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients |
| Q45875415 | Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. |
| Q34249813 | Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy |
| Q42112270 | Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. |
| Q80463889 | Relation of morning serum cortisol to prothrombotic activity in women with stable coronary artery disease |
| Q35686658 | Relationships of plasma factor VIIa-antithrombin complexes to manifest and future cardiovascular disease |
| Q36889043 | Structure-Function Relationship of the Interaction between Tissue Factor and Factor VIIa. |
| Q34552497 | The Eph tyrosine kinase receptors EphB2 and EphA2 are novel proteolytic substrates of tissue factor/coagulation factor VIIa |
| Q35792945 | The influence of biomaterials on endothelial cell thrombogenicity |
| Q34481022 | The plasma hemostatic proteome: thrombin generation in healthy individuals |
| Q37803133 | Thrombin Inhibitors from Different Animals |
| Q42723158 | Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well? |
| Q37438302 | Tissue factor in coagulation: Which? Where? When? |
| Q35091816 | Tissue factor residues that putatively interact with membrane phospholipids |
| Q37288296 | Tissue factor structure and function |
| Q36968186 | Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa |
| Q33726774 | Tissue factor-factor VIIa signaling |
| Q35684155 | Tissue factor: a key molecule in hemostatic and nonhemostatic systems |
| Q37444639 | Tissue factor: mechanisms of decryption |
| Q36744024 | Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa |
| Q41293004 | Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations |
| Q35755627 | rFVIIa transported from the blood stream into tissues is functionally active. |
Search more.